OLMA — Olema Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $556.35m
- $294.54m
- 42
- 25
- 51
- 34
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 4.32 | 21.5 | 71.5 | 107 | 105 |
Operating Profit | -4.32 | -21.5 | -71.5 | -107 | -105 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.32 | -22.1 | -71.1 | -105 | -96.7 |
Net Income After Taxes | -4.32 | -22.1 | -71.1 | -105 | -96.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.32 | -22.1 | -71.1 | -105 | -96.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.32 | -24 | -71.1 | -105 | -96.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.112 | -0.623 | -1.8 | -2.62 | -2.14 |
Dividends per Share |